Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
Rowinsky EK, Humphrey R, Hammond LA, Aylesworth C, Smetzer L, Hidalgo M, Morrow M, Smith L, Garner A, Sorensen JM, Von Hoff DD, Eckhardt SG. Rowinsky EK, et al. Among authors: eckhardt sg. J Clin Oncol. 2000 Jan;18(1):178-86. doi: 10.1200/JCO.2000.18.1.178. J Clin Oncol. 2000. PMID: 10623708 Clinical Trial.
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA 3rd, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD. Rothenberg ML, et al. Among authors: eckhardt sg. J Clin Oncol. 1996 Apr;14(4):1128-35. doi: 10.1200/JCO.1996.14.4.1128. J Clin Oncol. 1996. PMID: 8648367 Clinical Trial.
A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium.
Eckhardt SG, Burris HA, Eckardt JR, Weiss G, Rodriguez G, Rothenberg M, Rinaldi D, Barrington R, Kuhn JG, Masuo K, Sudo K, Atsumi R, Oguma T, Higashi L, Fields S, Smetzer L, Von Hoff DD. Eckhardt SG, et al. Ann Oncol. 1996 Jul;7(5):491-6. doi: 10.1093/oxfordjournals.annonc.a010638. Ann Oncol. 1996. PMID: 8839904 Free article. Clinical Trial.
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Eckhardt SG, Baker SD, Eckardt JR, Burke TG, Warner DL, Kuhn JG, Rodriguez G, Fields S, Thurman A, Smith L, Rothenberg ML, White L, Wissel P, Kunka R, DePee S, Littlefield D, Burris HA, Von Hoff DD, Rowinsky EK. Eckhardt SG, et al. Clin Cancer Res. 1998 Mar;4(3):595-604. Clin Cancer Res. 1998. PMID: 9533526 Clinical Trial.
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.
Villalona-Calero MA, Baker SD, Hammond L, Aylesworth C, Eckhardt SG, Kraynak M, Fram R, Fischkoff S, Velagapudi R, Toppmeyer D, Razvillas B, Jakimowicz K, Von Hoff DD, Rowinsky E. Villalona-Calero MA, et al. Among authors: eckhardt sg. J Clin Oncol. 1998 Aug;16(8):2770-9. doi: 10.1200/JCO.1998.16.8.2770. J Clin Oncol. 1998. PMID: 9704730 Clinical Trial.
Alternative dosing schedules for irinotecan.
Rothenberg ML, Kuhn JG, Schaaf LJ, Drengler RL, Eckhardt SG, Villalona-Calero MA, Hammond L, Miller LL, Petit RG, Rowinsky EK, Von Hoff DD. Rothenberg ML, et al. Among authors: eckhardt sg. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):68-71. Oncology (Williston Park). 1998. PMID: 9726095 Free article. Review.
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, Drengler R, Stephenson J Jr, Harding MW, Von Hoff DD. Rowinsky EK, et al. Among authors: eckhardt sg. J Clin Oncol. 1998 Sep;16(9):2964-76. doi: 10.1200/JCO.1998.16.9.2964. J Clin Oncol. 1998. PMID: 9738565 Clinical Trial.
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.
Rothenberg ML, Sharma A, Weiss GR, Villalona-Calero MA, Eckardt JR, Aylesworth C, Kraynak MA, Rinaldi DA, Rodriguez GI, Burris HA 3rd, Eckhardt SG, Stephens CD, Forral K, Nicol SJ, Von Hoff DD. Rothenberg ML, et al. Among authors: eckhardt sg. Ann Oncol. 1998 Jul;9(7):733-8. doi: 10.1023/a:1008286908930. Ann Oncol. 1998. PMID: 9739439 Free article. Clinical Trial.
362 results